Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

This study has been terminated.
Information provided by (Responsible Party):
Seaside Therapeutics, Inc. Identifier:
First received: March 1, 2012
Last updated: July 30, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)